Related Experiment Videos
Prednimustine in mycosis fungoides: a report from the Scandinavian mycosis fungoides study group
Acta Dermato-Venereologica
|January 1, 1979
Abstract:
Prednimustine, a chlorambucil ester of prednisolone, was administered orally to 5 patients with mycosis fungoides in advanced tumour stage. Partial remission was obtained in 2 of the patients. However, we do not consider the agent to be particularly advantageous for the treatment of mycosis fungoides.
Insights
Prednimustine, an oral treatment combining chlorambucil and prednisolone, showed partial remission in 2 out of 5 advanced mycosis fungoides patients. This agent is not considered particularly advantageous for treating this skin lymphoma.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Mycosis fungoides is a type of cutaneous T-cell lymphoma.
- Advanced stages of mycosis fungoides present significant treatment challenges.
Purpose of the Study:
- To evaluate the efficacy of prednimustine in patients with advanced mycosis fungoides.
- To assess the clinical benefit of this chlorambucil-prednisolone ester in a small patient cohort.
Main Methods:
- Oral administration of prednimustine.
- Treatment of 5 patients diagnosed with mycosis fungoides in advanced tumor stage.
Main Results:
- Partial remission was observed in 2 out of the 5 treated patients.
- The overall response rate indicates limited efficacy.
Conclusions:
- Prednimustine demonstrated minimal therapeutic benefit in this advanced mycosis fungoides cohort.
- The agent is not considered particularly advantageous for treating advanced mycosis fungoides.